- Home
- AOMR vs CLLS Comparison
AOMR vs CLLS Comparison
Compare AOMR & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AOMR | CLLS |
|---|---|---|
| Founded | 2018 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 224.3M | 299.0M |
| IPO Year | 2021 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AOMR | CLLS |
|---|---|---|
| Price | $8.67 | $4.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $11.13 | $8.50 |
| AVG Volume (30 Days) | 95.6K | ★ 121.0K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | ★ 14.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | $34,705,000.00 | ★ $82,551,000.00 |
| Revenue This Year | N/A | $32.58 |
| Revenue Next Year | $16.56 | $20.68 |
| P/E Ratio | $11.77 | ★ N/A |
| Revenue Growth | N/A | ★ 129.04 |
| 52 Week Low | $7.36 | $1.10 |
| 52 Week High | $10.88 | $5.48 |
Technical Indicators
Market Signals| Indicator | AOMR | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 56.30 |
| Support Level | $8.68 | $4.47 |
| Resistance Level | $8.80 | $5.45 |
| Average True Range (ATR) | 0.14 | 0.29 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 34.33 | 60.39 |
Price Performance
Historical ComparisonAbout AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.